Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • April Psychedelic Capital investigates clinical trials & RWE & Going Mainstream: Mass Adoption
  • The next edition of the psychedelic investment series will be on Thursday, April 29, 2021, at 1:30 pm ET
  • The PsyCap April edition will feature engaging presentations from NanoPsy, BetterLife Pharma Inc (BETR), PharmAla Biotech
  • Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space
  • BetterLife Pharma Inc. is up 7.94 per cent and is trading at C$0.68 at 11:36 am ET

Microdose Psychedelic Insights, in partnership with The Conscious Fund, is pleased to present the next edition of Psychedelic Capital.

The next edition of the psychedelic investment series will be on Thursday, April 29, 2021, at 1:30 pm ET.

The PsyCap April edition will feature engaging presentations from NanoPsy, BetterLife Pharma Inc (BETR), PharmAla Biotech, as well as panel discussions on the topic of Clinical Trials & RWE and Going Mainstream: Mass Adoption.

Details and schedule of the April PsyCap are as follows: 1:45 pm, BetterLife Pharma Inc.

As the schedule that day unfolds, 3:15 pm will be dedicated to, Going Mainstream: Mass Adoption. Features Richard Skaife, Ronan Levy, Kathryn Tucker, Dustin Robinson.

“While PharmAla Biotech has a great team behind it, we’re a relatively new company,” said Nicholas Kadysh, President of PharmAla Biotech.

“I’m excited to bring our story to the PsyCap audience, and to talk with Justin Ling about what I see as the future of the industry,” added Kadysh.

Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience.

Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.

Live networking with all the attendees is available prior to and during the event.

Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. 

This online event programming is dedicated to providing investment-grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. 

BetterLife Pharma Inc. is up 7.94 per cent and is trading at C$0.68 at 11:36 am ET.

More From The Market Herald

" BioHarvest Sciences (CSE:BHSC) appoints Steven Lehrer to its advisory board

BioHarvest Sciences (BHSC) has appointed Steven Lehrer as its newest advisory board member, effective immediately.

" CloudMD (TSXV:DOC) Receives U.S. patent approval

CloudMD Software & Services Inc. (DOC) has received US patent approval for its Real Time Intervention Platform.

" NervGen Pharma (TSXV:NGEN) introduces Spinal Cord Injury Board

NervGen Pharma Corp. (NGEN) has introduced its Spinal Cord Injury (SCI) Clinical Advisory Board.
Medicenna Therapeutics Corp - CEO, Fahar Merchant

" Medicenna (TSX:MDNA) receives FDA clearance to expand MDNA11 study

Medicenna Therapeutics (MDNA) has received FDA approval to expand the Phase 1/2 ABILITY study of MDNA11 to clinical trial sites in the US.